Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN91EK)

• Drug Name: SK&F-104856 Drug Info
• Synonyms: SK-104856
• Cross-matching ID:
  PubChem CID: 126225
  CAS Number: CAS 136427-58-2
  TTD Drug ID: DMN91EK

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-1B (ADRA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methamphetamine	DMPM4SK	Anxiety		Approved	[3]
Propericiazine	DME9JNL	Psychiatric disorder	6E8Z	Approved	[4]
Methoxamine	DMF5XQH	Hypertension	BA00-BA04	Approved	[5]
Phendimetrazine	DM6TS1N	Obesity	5B81	Approved	[6]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[7]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[8]
Sunepitron	DM6M8ZX	N. A.	N. A.	Discontinued in Phase 3	[9]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[10]
SOU-001	DMPAEK5	Urinary incontinence	MF50.2	Discontinued in Phase 2	[11]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[1]

Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxazosin	DM9PLRH	Benign prostatic hyperplasia	GA90	Approved	[12]
Armodafinil	DMGB035	Malignant glioma	2A00.0	Approved	[13]
Alfuzosin	DMZVMKF	Benign prostatic hyperplasia	GA90	Approved	[14]
Moxisylyte	DMFCLYW	Erectile dysfunction	HA01.1	Approved	[15]
Terazosin	DM3JCVS	Benign prostatic hyperplasia	GA90	Approved	[16]
Bunazosin	DM4I8O7	Glaucoma/ocular hypertension	9C61	Approved	[17]
Trimazosin	DM1QLST	Congestive heart failure	BD10	Approved	[18]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[7]
DL-017	DMM8GZT	Hypertension	BA00-BA04	Phase 1	[19]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[20]

Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SILODOSIN	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[21]
NAFTOPIDIL	DMQ8R4E	Hypertension	BA00-BA04	Approved	[21]
Tamsulosin	DM5QF9V	Benign prostatic hyperplasia	GA90	Approved	[22]
Xatral	DMLHOA0	Benign prostatic hyperplasia	GA90	Approved	[23]
Dutasteride + tamsulosin	DM6P8HU	Benign prostatic hyperplasia	GA90	Phase 3	[24]
Besipirdine	DMLVNTA	Cognitive impairment	6D71	Phase 3	[25]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[7]
PMID30124346-Compound-LDT8	DM5MUNG	Benign prostatic hyperplasia	GA90	Patented	[20]
PMID30124346-Compound-LDT66	DMJMTNL	Benign prostatic hyperplasia	GA90	Patented	[20]
TIOSPIRONE	DME5QDP	N. A.	N. A.	Discontinued in Phase 3	[8]

Drug(s) Affected By Alpha-1D adrenergic receptor (ADRA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alfuzosin	DMZVMKF	Benign prostatic hyperplasia	GA90	Approved	[2]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[26]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[27]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[28]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[29]
Terbutaline	DMD4381	Asthma	CA23	Approved	[30]
Methoxamine	DMF5XQH	Hypertension	BA00-BA04	Approved	[28]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[26]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[30]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[28]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1A (ADRA1A)	TTNGILX	ADA1A_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-1B (ADRA1B)	TTBRKXS	ADA1B_HUMAN	Inhibitor	[1]
Adrenergic receptor alpha-1D (ADRA1D)	TT34BHT	ADA1D_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-1D adrenergic receptor (ADRA1D)	OTW2CD1O	ADA1D_HUMAN	Protein Interaction/Cellular Processes	[2]

References

• [1] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [2] The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.
• [3] Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
• [4] Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
• [5] Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
• [6] Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
• [7] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [8] 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
• [9] An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
• [10] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [11] Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
• [12] The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
• [13] Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
• [14] Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
• [15] Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
• [16] Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
• [17] Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
• [18] The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
• [19] Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
• [20] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [21] Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
• [22] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [23] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [24] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [25] Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
• [26] Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. doi: 10.1161/01.cir.97.13.1227.
• [27] Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. doi: 10.1016/j.cardiores.2004.05.014.
• [28] Chromatography studies on bio-affinity of nine ligands of alpha1-adrenoceptor to alpha1D subtypes overexpressed in cell membrane. Sci China C Life Sci. 2004 Aug;47(4):376-81. doi: 10.1360/03yc0109.
• [29] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [30] Neuroendocrine mediators up-regulate alpha1b- and alpha1d-adrenergic receptor subtypes in human monocytes. J Neuroimmunol. 1999 Mar 1;95(1-2):165-73. doi: 10.1016/s0165-5728(99)00011-9.